Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated